特瑞普利单抗联合白蛋白紫杉醇及贝伐珠单抗治疗晚期黑色素瘤的回顾性研究
该回顾性研究纳入41例不可手术的Ⅲ/Ⅳ期黑色素瘤患者,接受特瑞普利单抗联合白蛋白结合型紫杉醇及贝伐珠单抗治疗,部分联合个体化放疗。确认的ORR为63.4%,DCR为92.7%,中位PFS为14.2个月,1年生存率75.5%,2年生存率54.6%。肝转移、MET突变和NF1突变是PFS的独立预测因素。
要点
- 三药联合方案在晚期黑色素瘤中ORR 63.4%、DCR 92.7%,中位PFS 14.2个月。
- 联合放疗者中位PFS 14.3个月,未放疗者7.0个月(HR=0.45)。
- 肝转移、MET突变、NF1突变是PFS独立预测因素(P=0.006、0.038、0.002)。
核心结论
- 特瑞普利单抗联合白蛋白结合型紫杉醇和贝伐珠单抗对晚期黑色素瘤具有较好疗效和可接受毒性。
- 该三联方案联合放疗可显著改善PFS。
- 肝转移、MET或NF1突变患者可能从该方案获益较少。
研究设计与样本
- 回顾性研究,纳入2020年9月至2023年8月在南京大学医学院附属鼓楼医院接受治疗的41例经病理确诊、ECOG PS 0-2、不可手术的Ⅲ或Ⅳ期黑色素瘤患者。
- 治疗方案为白蛋白结合型紫杉醇、贝伐珠单抗和特瑞普利单抗每3周1次,6-8周期后未进展或不可耐受者予以贝伐珠单抗和特瑞普利单抗维持治疗,期间根据病情给予个体化放疗。
- 主要终点为经确认的客观缓解率(ORR)和疾病控制率(DCR)。
主要发现
- 41例患者中28例肿瘤缩小,4.9%(2/41)达完全缓解,63.4%(26/41)达部分缓解。
- 确认的ORR为63.4%(95% CI:46.9%-77.9%),DCR为92.7%(95% CI:80.1%-98.5%)。
- 中位PFS为14.2个月,1年生存率75.5%(95% CI:62.7%-90.9%),2年生存率54.6%(95% CI:38.1%-78.1%)。
- 接受放疗者中位PFS为14.3个月,未接受放疗者为7.0个月(HR=0.45,95% CI:0.20-1.01)。
- 3级以上治疗相关不良事件包括白细胞减少、中性粒细胞减少、AST/ALT升高、肾上腺皮质功能不全、高甘油三酯血症和神经毒性,未观察到治疗相关死亡。
关键数值与推荐
- 生物标志物分析显示肝转移、MET突变和NF1突变是PFS的独立预测因素(P分别为0.006、0.038、0.002)。
临床怎么用
- 对于晚期黑色素瘤患者,可考虑特瑞普利单抗联合白蛋白结合型紫杉醇及贝伐珠单抗方案,并根据病情联合个体化放疗。
- 治疗前可关注肝转移状态及MET、NF1突变情况,以辅助评估获益可能性。
局限性
- 回顾性研究,样本量较小(41例),证据等级有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: Advanced malignant melanoma still poses significant challenges in treatment. Combining nab-paclitaxel, bevacizumab, and immunotherapy has shown promising efficacy across various cancer types. This retrospective study aimed to assess the efficacy and safety of this regimen in patients with advanced melanoma and explore related biomarkers. Methods: Patients with histologically confirmed inoperable stage Ⅲ or Ⅳ melanoma and Eastern Cooperative Oncology Group Performance Status 0-2 were included in this retrospective study conducted from September 2020 to August 2023. Patients received combination therapy with nab-paclitaxel, bevacizumab, and toripalimab (Q3W) at Nanjing Drum Tower Hospital. Maintenance therapy with bevacizumab and toripalimab was given after 6-8 cycles without disease progression or intolerable adverse reactions. Personalized radiotherapy was delivered. The primary endpoint was the confirmed objective response rate (ORR) and disease control rate (DCR). Results: As of January 20, 2024, 28 out of 41 patients showed tumor shrinkage, including 4.9% (n=2) achieving complete response (CR) and 63.4% (n=26) achieving partial response (PR). The confirmed ORR was 63.4% (95% CI: 46.9%-77.9%) and the DCR was 92.7% (95% CI: 80.1%-98.5%). The median PFS was 14.2 months, the 1-year survival rate was 75.5% (95% CI: 62.7%-90.9%), and the 2-year survival rate was 54.6% (95% CI: 38.1%-78.1%). Moreover, patients who received radiotherapy exhibited a longer median progression-free survival (mPFS) (14.3 months vs 7.0 months, HR=0.45 [95% CI: 0.20-1.01]). Grade 3 treatment-related adverse events were leukopenia, neutropenia, AST/ALT elevation, adrenal insufficiency, hypertriglyceridemia and neurotoxicity. No treatment-related deaths were observed. In addition, biomarker analysis showed that liver metastasis, MET mutation, and NF1 mutation were independent predictors of PFS (P=0.006, 0.038, and 0.002, respectively). Conclusions: This study demonstrates that toripalimab, in combination with nab-paclitaxel and bevacizumab, offers a potential therapeutic option for advanced melanoma with acceptable toxicity. Furthermore, this triplet therapy combined with radiotherapy significantly improves PFS. Preliminary biomarker analysis suggests that patients with liver metastasis, MET or NF1 mutations may be less likely to benefit from this treatment regimen. 目的: 评估白蛋白结合型紫杉醇、贝伐珠单抗联合免疫治疗在晚期黑色素瘤患者中的疗效和安全性,并探索相关生物标志物。 方法: 纳入41例于2020年9月至2023年8月在南京大学医学院附属鼓楼医院接受白蛋白结合型紫杉醇、贝伐珠单抗和特瑞普利单抗联合治疗(每3周1次)的患者。所有患者均为经病理确诊、美国东部肿瘤协作组功能状态评分0~2分、无法手术的Ⅲ或Ⅳ期黑色素瘤患者。三药联合治疗6~8个周期后若未出现疾病进展或无法耐受的不良反应,则予以贝伐珠单抗和特瑞普利单抗维持治疗。治疗期间根据病情给予个体化放疗。主要终点为经确认的客观缓解率(ORR)和疾病控制率(DCR)。 结果: 截至2024年1月20日,41例患者中28例出现肿瘤缩小,其中4.9%(2/41)达到完全缓解,63.4%(26/41)达到部分缓解。经确认的ORR为63.4%(95% CI:46.9%~77.9%),DCR为92.7%(95% CI:80.1%~98.5%)。中位无进展生存时间(PFS)为14.2个月,1年生存率为75.5%(95% CI:62.7%~90.9%),2年生存率为54.6%(95% CI:38.1%~78.1%)。接受放疗的患者中位PFS更长,为14.3个月(未接受放疗者中位PFS为7.0个月,HR=0.45,95% CI:0.20~1.01)。3级以上治疗相关不良事件包括白细胞减少、中性粒细胞减少、天门冬氨酸氨基转移酶/谷氨酸氨基转移酶升高、肾上腺皮质功能不全、高甘油三酯血症和神经不良反应。未观察到治疗相关死亡病例。此外,生物标志物分析显示,肝转移、MET突变和NF1突变是PFS的独立预测因素(均P<0.05)。 结论: 特瑞普利单抗联合白蛋白结合型紫杉醇和贝伐珠单抗对晚期恶性黑色素瘤具有较好的疗效和安全性,且该三联用药联合放疗可显著改善患者的PFS,为晚期黑色素瘤患者的治疗提供了新的选择。伴有肝转移、携带MET或NF1突变的患者复发风险更高、生存期更短。.
引用
- Ren Y, Zhao LJ, Wei ZM, et al. [A retrospective study of PD-1 monoclonal antibody combined with nab-paclitaxel plus bevacizumab in the treatment of advanced malignant melanoma]. Zhonghua Zhong Liu Za Zhi. 2026. PMID: 42086527. doi:10.3760/cma.j.cn112152-20250723-00359
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。